ReviewJournal of clinical medicine2021
Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD).
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 56 citations in OpenAlex.
- Prognostic impact of autoimmune features in interstitial lung disease: a single-center retrospective real-world cohort study.Clinical rheumatology · 2026Article
- Radiological diversity in rheumatoid arthritis associated with usual interstitial pneumonia (RA-UIP) and its therapeutic implications: towards a generalizable framework of interstitial lung disease treatment.Respiratory research · 2026Review
- Efficacy of Janus kinase inhibitors in the treatment of acute exacerbations of rheumatoid arthritis-associated interstitial lung disease: a retrospective observational case series.Frontiers in immunology · 2026Observational
- Baricitinib alleviates interstitial lung disease in CIA mice by inhibiting macrophage polarization and increase exosomal miR-126a-3p with anti-fibrotic activityFrontiers in pharmacology · 2026Article
- A House of Cards: Radiographic Foundations of Personalized Therapy in Autoimmune Interstitial Lung Disease.Annals of the American Thoracic Society · 2025Article
- Serum CYFRA21-1 as a novel biomarker for predicting progressive pulmonary fibrosis in non-IPF interstitial lung disease, a cohort study.BMC pulmonary medicine · 2025Article
- Differential impacts of interstitial lung disease and airway disease on rheumatoid arthritis disease activity and infection.Scientific reports · 2025Article
- Precision medicine in rheumatoid arthritis-associated interstitial lung disease: current evidence and future directions.Current opinion in pulmonary medicine · 2025Review
- Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study.Seminars in arthritis and rheumatism · 2025Article
- Article
- Exploring Antifibrotic Strategies for Interstitial Lung Disease in Rheumatoid Arthritis: A Narrative Review.Open access rheumatology : research and reviews · 2025Review
- Correlation of CT-based radiomics analysis with pathological cellular infiltration in fibrosing interstitial lung diseases.Japanese journal of radiology · 2024Article
- The Therapeutic Efficacy of Abatacept for Rheumatoid Arthritis-Associated Interstitial Lung Disease: Insights from a 12-Month Trial Using Semi-Quantitative Chest High-Resolution Computed Tomography Imaging.Journal of clinical medicine · 2024Article
- Successful treatment of rheumatoid arthritis-associated interstitial lung disease with filgotinib: A case report on janus kinase 1 inhibition.Respirology case reports · 2024Article
- A Systematic Review of the Key Predictors of Progression and Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease.Diagnostics (Basel, Switzerland) · 2024Review
- Risk factors of mortality in patients with rheumatoid arthritis-associated interstitial lung disease: a single-centre prospective cohort study.Arthritis research & therapy · 2024Article
- Proposed Clinical Algorithm for Pleuroparenchymal Fibroelastosis (PPFE).Journal of clinical medicine · 2024Review
- Do Ultrasound Lung Abnormalities Correlate to Biomarkers and Male Gender in Rheumatoid Arthritis Patients? A Monocentric Cross-Sectional Study.Journal of clinical medicine · 2024Article
- Methotrexate toxicity complicating a case of rheumatoid arthritis associated Interstitial Lung Disease: Lessons to learn.Radiology case reports · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a common type of autoimmune arthritis. Patient clinical outcomes might be influenced by numerous respiratory diseases, but interstitial lung disease (ILD) is the most important comorbidity. RA-associated ILD (RA-ILD) is divided into acute/subacute and chronic forms. In the acute/subacute course, if the disease is severe as indicated by a diffuse alveolar damage pattern, high-dose corticosteroids combined with antimicrobial agents should be promptly initiated while considering the differential diagnoses, primarily acute exacerbation (AE) of RA-ILD, drug-induced pneumonitis, and Pneumocystis pneumonia. As initial therapeutic management in the chronic course, the RA itself should be stabilized without delay; thereafter, the activity of ILD itself can be stabilized, considering the safety of each anti-rheumatic drug. The formation of the usual interstitial pneumonia (UIP) pattern is the most important determinant because lung function can worsen more quickly with this pattern. However, because clinicians can fail to identify specific radiological patterns, it is important to determine whether each patient with RA-ILD has UIP-like lesions such as subpleural reticulation, traction bronchiectasis, and honeycombing especially progressively enlarged cysts. In patients with progressive RA-ILD and high risk for infection or AE of ILD in whom fibrosis is dominant, clinicians should consider starting an anti-fibrotic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.